Bristol-Myers Squibb Pharmaceutical Limited

Bristol-Myers Squibb House, Uxbridge Business Park, Sanderson Road, Uxbridge, Middlesex, UB8 1DH , UK
Telephone: +44 (0)1895 523 000
Fax: +44 (0)1895 523 010
Medical Information Direct Line: +44 (0)1895 523 740
Medical Information e-mail: medical.information@bms.com
Medical Information Fax: +44 (0)1895 523 677

Patient Information Leaflet last updated on the eMC: 08/04/2011
PIL Zerit 20 mg, 30 mg and 40 mg Hard Capsules

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 08/04/2011 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
  • Change to storage instructions
  • Change to information about driving or using machinery
Updated on 12/11/2010 and displayed until 08/04/2011
Reasons for adding or updating:
  • Change of manufacturer
  • Change to storage instructions
Updated on 04/10/2010 and displayed until 12/11/2010
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
Updated on 03/06/2010 and displayed until 04/10/2010
Reasons for adding or updating:
  • Change of manufacturer
Updated on 18/01/2010 and displayed until 03/06/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 26/08/2008 and displayed until 18/01/2010
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
   stavudine